Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor in NASH and fibrosis
NCT02704403Phase 3Terminated
- Sponsor
- Genfit
- Start
- Mar 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of elafibranor in Nonalcoholic steatohepatitis (NASH), sponsored by Genfit. Started Mar 2016; status: terminated.
02
Drugs
elafibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02704403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02704403.